CA2667053C - Talarazole metabolites - Google Patents

Talarazole metabolites Download PDF

Info

Publication number
CA2667053C
CA2667053C CA2667053A CA2667053A CA2667053C CA 2667053 C CA2667053 C CA 2667053C CA 2667053 A CA2667053 A CA 2667053A CA 2667053 A CA2667053 A CA 2667053A CA 2667053 C CA2667053 C CA 2667053C
Authority
CA
Canada
Prior art keywords
compound according
talarozole
pharmaceutically acceptable
acceptable salt
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2667053A
Other languages
English (en)
French (fr)
Other versions
CA2667053A1 (en
Inventor
Debra Barrett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stiefel Laboratories Inc
Original Assignee
Stiefel Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stiefel Laboratories Inc filed Critical Stiefel Laboratories Inc
Publication of CA2667053A1 publication Critical patent/CA2667053A1/en
Application granted granted Critical
Publication of CA2667053C publication Critical patent/CA2667053C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2667053A 2006-10-17 2007-10-17 Talarazole metabolites Expired - Fee Related CA2667053C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85198906P 2006-10-17 2006-10-17
US60/851,989 2006-10-17
PCT/US2007/081685 WO2008049027A1 (en) 2006-10-17 2007-10-17 Talarazole metabolites

Publications (2)

Publication Number Publication Date
CA2667053A1 CA2667053A1 (en) 2008-04-24
CA2667053C true CA2667053C (en) 2015-04-28

Family

ID=39314359

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2667053A Expired - Fee Related CA2667053C (en) 2006-10-17 2007-10-17 Talarazole metabolites

Country Status (10)

Country Link
US (2) US8188124B2 (enExample)
EP (1) EP2114895A4 (enExample)
JP (1) JP5343267B2 (enExample)
KR (1) KR101419965B1 (enExample)
CN (1) CN101611016B (enExample)
AU (1) AU2007311026B2 (enExample)
BR (1) BRPI0718310A2 (enExample)
CA (1) CA2667053C (enExample)
MX (1) MX2009004096A (enExample)
WO (1) WO2008049027A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
JP5769965B2 (ja) 2007-07-31 2015-08-26 ライフスキャン・インコーポレイテッドＬｉｆｅｓｃａｎ，Ｉｎｃ． ヒト胚性幹細胞の分化
CN101878298B (zh) 2007-11-27 2017-08-15 生命扫描有限公司 人胚胎干细胞的分化
KR101597731B1 (ko) 2008-02-21 2016-02-26 센토코 오르토 바이오테크 인코포레이티드 세포 부착, 배양 및 탈리를 위한 방법, 표면 개질 플레이트 및 조성물
AU2009267137A1 (en) 2008-06-30 2010-01-07 Centocor Ortho Biotech Inc. Differentiation of pluripotent stem cells
BRPI0919885A2 (pt) 2008-10-31 2015-08-11 Centocor Ortho Biotech Inc Diferenciação de células-tronco embrionárias humanas para a linhagem endócrina pancreática
KR102025158B1 (ko) 2008-10-31 2019-09-25 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 췌장 내분비 계통으로의 분화
PL2366022T3 (pl) 2008-11-20 2016-11-30 Sposoby i kompozycje do przyłączania i hodowli komórek na podłożach planarnych
JP2012509085A (ja) 2008-11-20 2012-04-19 ヤンセン バイオテツク，インコーポレーテツド マイクロキャリア上での多能性幹細胞の培養
AU2010276438B2 (en) 2009-07-20 2015-06-11 Janssen Biotech Inc. Differentiation of human embryonic stem cells
EP4410991A3 (en) 2009-12-23 2024-10-09 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
KR20130025375A (ko) 2010-03-01 2013-03-11 얀센 바이오테크 인코포레이티드 만능 줄기 세포로부터 유래된 세포의 정제 방법
WO2011143299A2 (en) 2010-05-12 2011-11-17 Centocor Ortho Biotech Inc. Differentiation of human embryonic stem cells
WO2012030538A2 (en) 2010-08-31 2012-03-08 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
PH12013500389A1 (en) 2010-08-31 2013-04-22 Janssen Biotech Inc Differentiation of human embryonic stem cells
PH12013500349A1 (en) 2010-08-31 2022-03-30 Janssen Biotech Inc Differentiation of pluripotent stem cells
US9248120B2 (en) 2011-08-23 2016-02-02 The Board Of Trustees Of The Leland Stanford Junior University Reversing intestinal inflammation by inhibiting retinoic acid metabolism
JP6441080B2 (ja) 2011-12-22 2018-12-19 ヤンセン バイオテツク，インコーポレーテツド 単一ホルモンのインスリン陽性細胞へのヒト胚性幹細胞の分化
JP6383292B2 (ja) 2012-03-07 2018-08-29 ヤンセン バイオテツク，インコーポレーテツド 多能性幹細胞の増殖及び維持のための明確な培地
MX358590B (es) 2012-06-08 2018-08-24 Janssen Biotech Inc Diferenciacion de celulas madre embrionarias humanas en celulas endocrinas pancreaticas.
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
JP6557147B2 (ja) 2012-12-31 2019-08-07 ヤンセン バイオテツク，インコーポレーテツド Ｈｂ９調節物を用いたヒト胚性幹細胞の膵臓内分泌細胞への分化
EP2938722B1 (en) 2012-12-31 2021-12-08 Janssen Biotech, Inc. Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells
SG10201709338RA (en) 2012-12-31 2017-12-28 Janssen Biotech Inc Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
CN117821369A (zh) 2014-05-16 2024-04-05 詹森生物科技公司 小分子增强胰腺内分泌细胞中的mafa表达的用途
MA45479A (fr) 2016-04-14 2019-02-20 Janssen Biotech Inc Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100365312B1 (ko) * 1996-06-27 2003-03-06 얀센 파마슈티카 엔.브이. N-[4-(헤테로아릴메틸)페닐]헤테로아릴아민
AP869A (en) * 1998-01-05 2000-09-04 Pfizer 2,3-Substituted indole compounds as anti-inflammatory and analgesic agents.
MXPA04005864A (es) * 2001-12-19 2004-10-29 Atherogenics Inc Derivados de charcona y su uso para tratar enfermedades.
US20060205945A1 (en) * 2004-05-14 2006-09-14 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
PL372356A1 (pl) * 2005-01-20 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods

Also Published As

Publication number Publication date
CA2667053A1 (en) 2008-04-24
US8399495B2 (en) 2013-03-19
AU2007311026B2 (en) 2012-05-17
EP2114895A4 (en) 2011-06-22
US20120283204A1 (en) 2012-11-08
KR101419965B1 (ko) 2014-07-16
KR20090068286A (ko) 2009-06-25
EP2114895A1 (en) 2009-11-11
MX2009004096A (es) 2009-06-16
JP2010506953A (ja) 2010-03-04
US20100292284A1 (en) 2010-11-18
BRPI0718310A2 (pt) 2013-11-19
AU2007311026A1 (en) 2008-04-24
JP5343267B2 (ja) 2013-11-13
US8188124B2 (en) 2012-05-29
CN101611016A (zh) 2009-12-23
WO2008049027A1 (en) 2008-04-24
CN101611016B (zh) 2012-01-25

Similar Documents

Publication Publication Date Title
CA2667053C (en) Talarazole metabolites
DE60106281T2 (de) Verfahren zur Behandlung eines Östrogenrezeptor-positiven Karzinoms
DE69717148T2 (de) 3-pyridylenantiomere und ihre verwendung als analgetika
US11548853B2 (en) Isoquinoline compounds and their use in treating AhR imbalance
FI67686B (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara fenetanolaminderivat
KR20210052507A (ko) 간 장애 치료
EP2987784A1 (de) Verbesserung der bioverfügbarkeit von wirkstoffen mit amidinfunktion in arzneimitteln
US8378112B2 (en) Glycyrrhetinic acid derivative and use thereof
EP4183785A1 (en) Novel n-heterocyclic bet bromodomain inhibitor, and preparation method therefor and medical use thereof
JPH085863B2 (ja) １４−アニソイルアコニンおよびそれを有効成分とする新規な鎮痛・抗炎症剤
US20020132797A1 (en) DNA-cleaving antitumor agents
He et al. Metabolism and disposition of moxonidine in Fischer 344 rats
WO2001070217A1 (en) Dna-cleaving antitumor agents
Scatina et al. Metabolic disposition of enciprazine, a non-benzodiazepine anxiolytic drug, in rat, dog and man
EP1412361B1 (de) Substituierte 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluoren-6-carbonsäurederivate als nmda-antagonisten
FR2508043A1 (fr) Derives d'aporphine efficaces par voie orale et leur procede de fabrication
WO2025097160A1 (en) Methods of enhancing levodopa therapeutic efficacy
HK40087840A (en) Novel n-heterocyclic bet bromodomain inhibitor, and preparation method therefor and medical use thereof
WO2025034606A2 (en) A clinically-translatable ros/rns molecular imaging agent using a radiolabeled derivative of edaravone (edv)
KR820001304B1 (ko) 펜아탄올아민의 제조방법
Lan et al. Metabolism of a Benzothiazine compound (SQ 11,579) by the Intact Rat, Isolated Perfused Rat Liver, and Rat-Liver Microsomes
Cox et al. The metabolism in animals and man of oxmetidine—A new histamine H2-receptor antagonist
WO2021144746A1 (en) Use of icrf-193 derivatives and pharmaceutical preparations containing thereof for the prevention of chronic cumulative cardiotoxicity caused by therapy with anthracycline anticancer drugs
LU84211A1 (fr) Composes d'aporphine efficaces par voie orales
DD283372A5 (de) Verfahren zur herstellung von aminoketonen und -alkoholen

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20161017